Last reviewed · How we verify
Epirubicin+Cyclophosphamide
Epirubicin and cyclophosphamide are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, commonly used as a combination regimen in breast cancer treatment.
Epirubicin and cyclophosphamide are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, commonly used as a combination regimen in breast cancer treatment. Used for Breast cancer (early-stage and metastatic), Lymphomas, Other solid tumors.
At a glance
| Generic name | Epirubicin+Cyclophosphamide |
|---|---|
| Also known as | EC |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Chemotherapy combination (anthracycline + alkylating agent) |
| Target | DNA (topoisomerase II for epirubicin; DNA alkylation for cyclophosphamide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Epirubicin is a topoisomerase II inhibitor and intercalating agent that inserts into DNA and prevents replication and transcription. Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division. Together, this combination (EC regimen) provides synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Breast cancer (early-stage and metastatic)
- Lymphomas
- Other solid tumors
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia (hair loss)
- Mucositis
- Cardiotoxicity (with epirubicin)
- Hemorrhagic cystitis (with cyclophosphamide)
- Infertility
- Secondary malignancy
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy (NA)
- A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: